Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation

Experimental Eye Research

Volumn 64, Issue 5, 1997, Pages 767-773

  Thompson, Charles D ^b   MacDonald, Timothy L ^b   Garst, Michael E ^a   Wiese, Anne ^a   Munk, Stephen A ^a  

^a ALLERGAN INC   (United States)

^b NONE

Author keywords

Adrenergic agonist; Allergy; Glaucoma medication; Metabolism; Oxidation

Indexed keywords

ADRENALIN; ALLERGEN; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMODIAQUINE; ANTIGEN; APRACLONIDINE; BRIMONIDINE; CLONIDINE;

ALLERGENICITY; ALLERGIC REACTION; ARTICLE; DRUG MECHANISM; GLAUCOMA; INTRAOCULAR PRESSURE; PRIORITY JOURNAL;

EID: 0031149150     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1006/exer.1996.0267     Document Type: Article

References (16)

1. Basketter, D., Dooms-Gppssens, A., Karlberg, A. and Lepoittevin, J. (1995). The chemistry of contact allergy: why is a molecule allergic? Contact Dermatitis 32, 65-73.
2. Becker, B. and Morton, R. (1966). Topical epinephrine in glaucoma suspects. Am. J. Ophthalmol. 62, 272-7.
3. Butler, P., Mannschreck, M., Lin, S., Hwang, I. and Alvarado, J. (1995). Clinical experience with the long-term use of 1% apraclonidine. Arch. Ophthalmol. 113, 293-6.
4. Chien, D., Homsy, J., Gluchowski, C. and Tang-Liu, D. (1990). Corneal and conjunctival/sceral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr. Eye Res. 9, 1051-9.
5. Harrison, A., Kitteringham, N., Clarke, J. and Park, B. (1992). The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 43, 1421-30.
6. Hurvitz, L., Kaufman, P., Robin, A., Weinreb, R., Crawford, K. and Shaw, B. (1991). New developments in the drug treatment of glaucoma. Drugs 41, 514-32.
7. Josephy, P., Eling, T. and Mason, R. (1983). Oxidation of p-aminophenol catalysed by horseradish peroxidase and prostaglandin synthase. Mol. Pharmacol 23, 461-6.
8. Kumar, G. (1994). Drug metabolizing enzyme systems in the eye. In: Ocular therapeutic and drug delivery. (Ed. Reddy, I. K.). Pp. 149-67. Technomic: Lancaster, PA.
9. Nelson, S. (1982). Metabolic activation and drug toxicity. J. Med. Chem. 25, 753-65.
10. O'Brien, P. (1991). Molecular mechanisms of quinone cytotoxicity. Chem. Biol. Interactions 80, 1-41.
11. Potter, D., Miller, D. and Hinson, J. (1986). Horseradish peroxidase-catalysed oxidation of acetaminophen to intermediates that form polymers or conjugate with glutathione. Mol. Pharmacol. 29, 155-61.
12. Riley, R. and Leeder, J. (1995). In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin. Exp. Immunol. 99, 1-6.
13. Robin, A., Pollack, I. and deFaller, J. (1987). Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. Arch. Ophthalmol. 105, 1208-11.
14. Ross, D., Larsson, R., Andersson, B., Nilsson, U., Lindquist, T., Lindeke, B. and Moldelus, P. (1985). The oxidation of p-phenetidine by horseradish peroxidase and prostaglandin synthase and the fat of glutathione during such oxidations. Biochem. Pharmacol 34, 343-51.
15. Samokyszyn, V., Freeman, J., Maddipati, K. and Lloyd, R. (1995). Peroxidase-catalysed oxidation of pentachlorophenol. Chem. Res. Toxicol. 8, 349-55.
16. Shelton, K., Ritch, R. and Robin, A. (1996). Efficacy of Brimonidine when added to maximally tolerated glaucoma medications. ARVO Abstracts Invest. Ophthalmol. Vis. Sci. 32, Abstract 5065.